WHO: Pneumonia of unknown cause—China. 2020. https://web.archive.org/web/20200107032945/https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (Last accessed on June13, 2020).
2.
ChenY, ZhaoM, WuY, ZangS: Epidemiological analysis of the early 38 fatalities in Hubei, China, of the coronavirus disease 2019. J Glob Health, 2020; 10:011004. DOI: 10.7189/jogh-10-011004.
3.
SchuchatA: Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR Morb Mortal Wkly Rep, 2020; 69. DOI: 10.1558/5/mmwr.mm6918e2.
4.
GiovanettiM, BenvenutoD, AngelettiS, CiccozziM: The first two cases of 2019-nCoV in Italy: where they come from?. J Med Virol, 2020; 92:518–521. DOI: 10.1002/jmv.25699.
5.
StoecklinSB, RollandP, SilueY, et al.: First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures. Eurosurveillance, 2020; 25:2000094. DOI: 10.2807/1560-7917.ES.2020.25.6.2000094.
6.
AlexanderSPH, ArmstrongJ, DavenportAP, et al.: A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29. Br J Pharmacol, 2020. DOI: 10.1111/bph.15094.
7.
RosaSGV, SantosWC: Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Pública, 2020; 44. DOI: 10.2663/3/RPSP.2020.40.
8.
Horbach SPJM: Pandemic Publishing: medical journals drastically speed up their publication process for Covid-19. bioRxiv. 2020. DOI: 10.1101/2020.04.18.045963.
YuB, LiC, ChenP, et al.: Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci, 2020. DOI: 10.1007/s11427-020-1732-2.
11.
MahévasM, TranV-T, RoumierM, et al.: Clinical efficacy of hydroxychloroquine in patients with Covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, 2020; 369. DOI: 10.1136/bmj.m1844.
12.
TangW, CaoZ, HanM, et al.: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020; 369. DOI: 10.1136/bmj.m1849.
13.
DerwandR, ScholzM: Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?. Med Hypotheses, 2020; 142:109815. DOI: 10.1016/j.mehy.2020.109815.
14.
ChanK, LaiS, ChuC, et al.: Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J, 2003; 9:399–406.
15.
CaoB, WangY, WenD, et al.: A Trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020. DOI: 10.1056/NEJMoa2001282.
16.
SiegelD, HuiHC, DoerfflerE, et al.: Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem, 2017; 60:1648–1661. DOI: 10.1021/acs.jmedchem.6b01594.
17.
AgostiniML, AndresEL, SimsAC, et al.: Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 2018; 9. DOI: 10.1128/mBio.00221-18.
18.
SheahanTP, SimsAC, GrahamRL, et al.: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 2017; 9. DOI: 10.1126/scitranslmed.aal3653.
19.
WangY, ZhangD, DuG, et al.: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020; 395:1569–1578. DOI: 10.1016/S0140-6736(20)31022-9.
